HIPRA is leading the European project SPEEDCELL (SPEEDy CELL line development for pandemic response), a name that plays on the English terms speedy and cell, with the goal of transforming the development of vaccines and other biotechnological products to address future health crises. The project seeks to establish a faster, more flexible, and more efficient production platform, capable of delivering new biologic products in just 100 days. 

With €3.96 million in funding through the European EU4Health program, SPEEDCELL addresses one of the major challenges of the European healthcare system: the need for agile and effective response mechanisms to global health emergencies. 

The initiative, which will run for 4 years, focuses on optimizing development and manufacturing processes based on cell lines, widely used in the production of vaccines and biological products. The ultimate objective is to make the so-called “100 Days Mission” a reality, promoted by the European Commission and the HERA (Health Emergency Preparedness and Response Authority), to ensure rapid access to critical medical countermeasures during emergencies.